Dove Medical Press reposted this
𝐖𝐞 𝐚𝐫𝐞 𝐩𝐥𝐞𝐚𝐬𝐞𝐝 𝐭𝐨 𝐚𝐧𝐧𝐨𝐮𝐧𝐜𝐞 𝐭𝐡𝐞 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐚 𝐧𝐞𝐰 𝐬𝐭𝐮𝐝𝐲 𝐢𝐧 𝐶𝑙𝑖𝑛𝑖𝑐𝑜𝐸𝑐𝑜𝑛𝑜𝑚𝑖𝑐𝑠 𝑎𝑛𝑑 𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑠 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝐨𝐧 𝐭𝐡𝐞 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐢𝐦𝐩𝐚𝐜𝐭 𝐨𝐟 𝐨𝐧𝐜𝐞-𝐰𝐞𝐞𝐤𝐥𝐲 𝐢𝐧𝐬𝐮𝐥𝐢𝐧 𝐢𝐜𝐨𝐝𝐞𝐜 𝐢𝐧 𝐈𝐭𝐚𝐥𝐲. This study explores the pharmacoeconomic impact and quality-of-life benefits of icodec, an innovative basal insulin with weekly administration. By reducing injection frequency from 365 to 52 times per year, icodec not only improves treatment adherence and patient satisfaction but also optimizes costs for the National Health Service (NHS). Key findings include: •𝐂𝐨𝐬𝐭 𝐒𝐚𝐯𝐢𝐧𝐠𝐬: Thanks to a reduction in needle consumption and improved adherence, icodec generates an annual economic benefit of approximately €105.95 per patient. •𝐂𝐨𝐬𝐭-𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞𝐧𝐞𝐬𝐬: With an incremental utility in terms of Quality-Adjusted Life Years (QALYs), icodec proves to be a cost-effective alternative, showing a dominant Incremental Cost-Effectiveness Ratio (ICER) over daily insulin degludec. •𝐄𝐧𝐯𝐢𝐫𝐨𝐧𝐦𝐞𝐧𝐭𝐚𝐥 𝐈𝐦𝐩𝐚𝐜𝐭: The reduced injection frequency also contributes to sustainability, decreasing CO2 emissions by approximately 62% per patient annually. This analysis demonstrates that icodec offers a valuable economic and therapeutic option for diabetes management in Italy, delivering enhanced quality of life without additional costs to the NHS. 🔎 Read the full study to explore these findings (link): https://lnkd.in/dA2f9u8U 𝐀𝐮𝐭𝐨𝐫𝐡𝐬: Enrico Torre, Sergio Di Matteo, Giacomo M. Bruno, Chiara Martinotti, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo #SAVE #HTA #HealthEconomics #Diabetes #Insulin #Adherence #QualityOfLife #Pharmacoeconomics #Sustainability #icodec #novonordisk Novo Nordisk Dove Medical Press DOVE MEDICAL PRESS LIMITED Maria Chiara Valentino Roberta Di Massa Davide Zelioli Emma Lucia Fogliati Alessandro Alfano
